Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18791193 | 1.00 | BLM (0.52) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL9333340 | 0.93 | LTA4H (0.50) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL7897955 | 0.91 | ACE2 (0.50) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL3693315 | 0.91 | ACE2 (0.50) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL4653508 | 0.91 | ACE2 (0.50) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL7203810 | 0.91 | ACE2 (0.50) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL28055059 | 0.90 | ACE2 (0.58) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL9248464 | 0.89 | BLM (0.43) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL287670 | 0.86 | — | — | |
| SCHEMBL27747322 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925771-B1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL SCIENT IND RES (IN) | 2021-08-18 | — | — | EP | claimed |
| EP-1383718-B1 | CONTINUOUS HYDROFORMYLATION PROCESS | DSM IP ASSETS BV (NL) | 2006-06-28 | — | — | EP | claimed |
| EP-1250377-B1 | PROCESS FOR THE PREPARATION OF A POLYAMIDE | DSM IP ASSETS BV (NL) | 2005-04-27 | — | — | EP | claimed |
| US-6828413-B2 | From a mixture of an aminocarbonamide and an aminocarboxylic acid and/or a lactam, that may be prepared by aminating a 5-formylvalerate or carbonylating, hydroformylating and aminating butadiene | OSM IP ASSETA, B.V. (NL) | 2004-12-07 | — | — | US | claimed |
| US-20040138508-A1 | Rapid, low temperature vacuum evaporator recovery of rhodium bisphosphite catalyst from high boiling point aldehydes without degradation | DSM I.P. ASSETS B.V. (NL) | 2004-07-15 | — | — | US | claimed |
| EP-1383718-A1 | CONTINUOUS HYDROFORMYLATION PROCESS | DSM IP Assets B.V. (NL) | 2004-01-28 | — | — | EP | claimed |
| CN-1411484-A | Process for preparation of polyamide | DSM NV (NL) | 2003-04-16 | — | — | CN | claimed |
| US-20030027977-A1 | Process for the preparation of a polyamide | DSM IP ASSETS B.V. (NL) | 2003-02-06 | — | — | US | claimed |
| WO-2002083605-A1 | CONTINUOUS HYDROFORMYLATION PROCESS | DSM IP ASSETS B.V. (NL) | 2002-10-24 | — | — | WO | claimed |
| EP-1250377-A1 | PROCESS FOR THE PREPARATION OF A POLYAMIDE | DSM N.V. (NL) | 2002-10-23 | — | — | EP | claimed |
| EP-0846096-A1 | HYDROFORMYLATION PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-06-10 | — | — | EP | claimed |
| EP-0846097-A1 | HYDROFORMYLATION PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-06-10 | — | — | EP | claimed |
| US-5698745-A | CONTACTING OLEFIN, HYDROGEN, CARBON MONOXIDE IN SOLVENT CONTAINING DISSOLVED CATALYST COMPRISING HALIDE-FREE PLATINUM COMPOUND, BIDENTATE DIARYLPHOSPHINE LIGAND HAVING FERROCENE BRIDGE, ACID PROMOTER TO PRODUCE LINEAR ALDEHYDE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-12-16 | — | — | US | claimed |
| US-5670700-A | USING PLATINUM COMPLEX CATALYST | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-09-23 | — | — | US | claimed |
| US-5618983-A | CONTACTING LINEAR OLEFIN COMPOUND, HYDROGEN, WATER AND CARBON MONOXIDE IN PRESENCE OF PLATINUM, PALLADIUM COMPOUNDS COMPLEXED WITH BIDENTATE DIARYL PHOSPHINE LIGANDS, AND AN ORGANO-METALLIC PROMOTER TO FORM LINEAR ALDEHYDE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-04-08 | — | — | US | claimed |
| WO-1997008127-A1 | HYDROFORMYLATION PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-06 | — | — | WO | claimed |
| WO-1997008124-A1 | HYDROFORMYLATION PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-06 | — | — | WO | claimed |
| WO-1997008123-A1 | HYDROFORMYLATION PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-06 | — | — | WO | claimed |
| EP-0363344-A1 | Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives | G.D. SEARLE & COMPANY (US) | 1990-04-11 | — | — | EP | claimed |
| US-4910310-A | Esterification of 2,3-O-isopropylidene-D-lyxono-1,4-lactone | G. D. SEARLE & CO. (US) | 1990-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138508-A1 | Rapid, low temperature vacuum evaporator recovery of rhodium bisphosphite catalyst from high boiling point aldehydes without degradation | VAPB, VAPA, MVD | BLM 4178/4885GABRR1 1534/4885CYP1A2 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.